Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment.
The trial demonstrated significant weight loss and a favorable safety profile, paving the way for a potential new class of oral non-incretin obesity medications.
CRB-913 is an orally delivered highly peripherally restricted CB1 inverse agonist for obesity.
Robust Efficacy and Consistent Weight Loss
The trial revealed rapid and consistent weight loss across all three dose levels over a 12-week period, showing no signs of plateauing. Patients taking the 60 mg dose achieved a placebo-adjusted mean weight reduction of 5.0%.
The 20 mg and 40 mg cohorts recorded reductions of 2.8% and 3.3%, respectively. All results showed strong statistical significance compared to placebo.
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Favorable Safety And Tolerability Profile
CRB-913 displayed fewer gastrointestinal adverse events compared to existing oral GLP-1 drugs.
Treatment discontinuation rates due to adverse events ranged from 3.1% to 13.1%. This aligns with approved GLP-1 therapies and remains substantially lower than the 13% to 42% rate seen with the discontinued drug monlunabant.
Psychiatric side effects were mild, infrequent, and transient. Out of 188 participants, researchers observed zero cases of suicidality and only one moderate instance of transient depressive symptoms.
Mild irritability ranked as the most common psychiatric effect. These results track closely with profiles of existing therapies like liraglutide, semaglutide, and tirzepatide.
Next Steps and FDA Engagement
The company will present detailed CANYON-1 trial data at ObesityWeek 2026 in mid-November.
Corbus Pharmaceuticals plans to consult with the FDA to launch a Phase 2 monotherapy trial in the first half of 2027.
Additionally, researchers will evaluate the potential of combining CRB-913 with existing GLP-1 therapies.
“In addition, more than 60% discontinue treatment within the first year. What I find particularly encouraging about the CANYON-1 study results is that weight reduction had not yet plateaued by the end of the 12-week treatment period, and that CRB-913 appears to have avoided the depressive effects associated with earlier central nervous system-acting cannabinoid receptor agonists,” said Harold Bays, an investigator on the CANYON-1 trial
CRBP Stock Price Activity: Corbus Pharmaceuticals shares were up 2.71% at $8.34 on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment